一分钟看懂
这是一项关于鼻咽癌的II 期研究，登记的药物或干预包括BL-B01D1；PD-1 monoclonal antibody；Gemcitabine；Cisplatin，当前状态为尚未开始招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BL-B01D1；PD-1 monoclonal antibody；Gemcitabine；Cisplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- 1. No gender restriction;
- 2. Age: ≥18 years and ≤75 years;
- 3. Expected survival time ≥3 months;
- 4. Pathologically confirmed as newly diagnosed nasopharyngeal carcinoma with "non-keratinizing carcinoma (WHO criteria)";
- 5. Patients with locally regionally advanced nasopharyngeal carcinoma(Stage T4N1M0 or T1-4N2-3M0(AJCC/UICC 9th edition));
- 6. Must have at least one measurable lesion as defined by RECIST v1.1;
- 7. Agree to provide archived tumor tissue specimens from primary or metastatic lesions within 1 year, or fresh tissue samples;
- 8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07797881；登记信息更新于 2026-09-16。